{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:10Z","timestamp":1781835130912,"version":"3.54.5"},"reference-count":17,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T00:00:00Z","timestamp":1361318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T00:00:00Z","timestamp":1361318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"Abstract<\/jats:title>\n \n Purpose:<\/jats:title>\n This study compared the intraocular pressure (IOP)-lowering efficacy of fixed-combination brinzolamide 1%\/brimonidine 0.2% (BBFC) with that of its component medications, brinzolamide and brimonidine, in patients with open-angle glaucoma or ocular hypertension.<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods:<\/jats:title>\n In this phase 3, multicenter, double-masked, parallel-group, 3-month study with a 3-month safety extension, eligible patients were randomized 1:1:1 to treatment with BBFC, brinzolamide, or brimonidine thrice daily after a washout period, during which any IOP-lowering medications were discontinued. The primary objectives of this study were to determine whether the IOP-lowering efficacy of BBFC was superior to that of brinzolamide alone and, separately, of brimonidine alone. IOP was assessed at 8:00 AM, 10:00 AM, 3:00 PM, and 5:00 PM at 2 weeks, 6 weeks, and 3 months after study drug initiation.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A total of 690 patients were enrolled in the study, and 615 completed the 3-month visit. Baseline mean IOP levels were similar among the 3 treatment groups at each of the 4 time points assessed. At the 3-month primary endpoint, mean IOP of the BBFC group was significantly lower than that of either the brinzolamide group or the brimonidine group (\n P<\/jats:italic>\n \u22640.005) across all time points. At the 2- and 6-week supportive endpoints, mean IOP of the BBFC group was significantly lower at all time points than the mean IOP of either the brinzolamide group (\n P<\/jats:italic>\n \u22640.01) or the brimonidine group (\n P<\/jats:italic>\n <0.0001). A total of 143 patients experienced at least 1 treatment-related adverse event (AE; BBFC group,\n n<\/jats:italic>\n =58, 26.2%; brinzolamide group,\n n<\/jats:italic>\n =44, 18.8%; brimonidine group,\n n<\/jats:italic>\n =41, 17.4%), the majority of which were ocular AEs.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n This study demonstrated that BBFC has significantly superior IOP-lowering activity compared with either brinzolamide 1% or brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension while providing a safety profile which is consistent with that of the individual components.<\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/jop.2012.0235","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T11:05:30Z","timestamp":1361358330000},"page":"290-297","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase 3 Randomized 3-Month Trial with an Ongoing 3-Month Safety Extension of Fixed-Combination Brinzolamide 1%\/Brimonidine 0.2%"],"prefix":"10.1177","volume":"29","author":[{"given":"Quang H.","family":"Nguyen","sequence":"first","affiliation":[{"name":"Scripps Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"McMenemy","sequence":"additional","affiliation":[{"name":"Lone Star Eye Care"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Realini","sequence":"additional","affiliation":[{"name":"West Virginia University Eye Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess T.","family":"Whitson","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center at Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Goode","sequence":"additional","affiliation":[{"name":"Alcon Research, Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,2,20]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.1.48"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.01.047"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.20"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600630304"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210701700311"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.4.418"},{"key":"e_1_3_3_10_2","unstructured":"Timolol maleate ophthalmic solution [package insert]. Fort Worth TX: Falcon Pharmaceuticals Ltd. 2004."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.050"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X301848"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.04.007"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00095-6"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(99)00107-1"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2005.21.337"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00381-0"},{"key":"e_1_3_3_18_2","unstructured":"ClinicalTrials.gov website. Brinzolamide\/brimonidine twice a day (BID) fixed combination (FC) vs. brinzolamide BID and brimonidine BID in patients with open angle glaucoma or ocular hypertension. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01310777. 2012 July 9."}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2012.0235","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2012.0235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2012.0235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:38:30Z","timestamp":1777646310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2012.0235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,20]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4,1]]}},"alternative-id":["10.1089\/jop.2012.0235"],"URL":"https:\/\/doi.org\/10.1089\/jop.2012.0235","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,20]]}}}